ALOXI OFFERS IMPROVED CINV CONTROL VERSUS ONDANSETRON1
- Pivotal, double-blind, controlled phase III clinical trial involved patients receiving moderately emetogenic chemotherapy.
- Patients were balanced across treatment groups.
EFFECTIVE EMESIS PREVENTION1
*97.5% Confidence Interval (CI) and two-sided Fisher's exact test (significance level=0.025) indicate a difference between ALOXI and ondansetron.
†Intent-to-treat cohort.
EARLY SEPARATION IN CONTROL RATES1
- ALOXI provided a significantly longer time to treatment failure than ondansetron (p<0.001).1
- Separation in control rates appeared as early as day 1.1
- Efficacy in the acute phase is a positive predicator of efficacy in the delayed phase.2
*Statistically significant vs ondansetron (p<0.001).
†Intent-to-treat cohort.
Click here to view the results of ALOXI vs. Dolasetron in Moderately Emetogenic Chemotherapy.
References
- Gralla R, Lichinitser M, Van der Vegt, S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
- Mantovani G, Macció A, Curreli L, et al. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus IM dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. Oncol Rep. 1998;5:273-280.